450 related articles for article (PubMed ID: 21151031)
1. An audience with...Francis Collins. Interviewed by Asher Mullard.
Collins F
Nat Rev Drug Discov; 2011 Jan; 10(1):14. PubMed ID: 21151031
[No Abstract] [Full Text] [Related]
2. National Institutes of Health. A government niche for translational medicine and drug development.
Kaiser J
Science; 2010 Dec; 330(6010):1462-3. PubMed ID: 21148358
[No Abstract] [Full Text] [Related]
3. Leveraging public private partnerships to innovate under challenging budget times.
Portilla LM; Rohrbaugh ML
Curr Top Med Chem; 2014; 14(3):326-9. PubMed ID: 24283971
[TBL] [Abstract][Full Text] [Related]
4. Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare.
Wellenreuther R; Keppler D; Mumberg D; Ziegelbauer K; Lessl M
Drug Discov Today; 2012 Nov; 17(21-22):1242-8. PubMed ID: 22521665
[TBL] [Abstract][Full Text] [Related]
5. Embrace change.
Nature; 2011 Mar; 471(7337):135. PubMed ID: 21390083
[No Abstract] [Full Text] [Related]
6. Re-engineering drug discovery and development.
FitzGerald GA
LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
[TBL] [Abstract][Full Text] [Related]
7. NerveCenter: At a glance: NIH programs supporting translational research in neurological disease.
Ann Neurol; 2010 Sep; 68(3):A9. PubMed ID: 20818783
[No Abstract] [Full Text] [Related]
8. NIH encourages translational collaboration with industry.
Wadman M
Nat Rev Drug Discov; 2010 Apr; 9(4):255-6. PubMed ID: 20224566
[No Abstract] [Full Text] [Related]
9. Drug development needs a new brand of science.
Fitzgerald G
Nature; 2010 Dec; 468(7326):869. PubMed ID: 21164436
[No Abstract] [Full Text] [Related]
10. David Haslam. Interview by Asher Mullard.
Haslam D
Nat Rev Drug Discov; 2013 Jul; 12(7):500. PubMed ID: 23764976
[No Abstract] [Full Text] [Related]
11. The bridge between lab and clinic. Interview by Meredith Wadman.
Collins F
Nature; 2010 Dec; 468(7326):877. PubMed ID: 21164451
[No Abstract] [Full Text] [Related]
12. U.S. science policy. Collins sparks furor with proposed NIH reshuffling.
Kaiser J
Science; 2011 Jan; 331(6016):386. PubMed ID: 21273458
[No Abstract] [Full Text] [Related]
13. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
Hedner T; Gatenbeck L
Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
[No Abstract] [Full Text] [Related]
14. Partnerships: beyond the buzzword.
Freire MC
Sci Transl Med; 2014 Jun; 6(242):242ed15. PubMed ID: 24964987
[No Abstract] [Full Text] [Related]
15. Into the valley of death: research to innovation.
Hudson J; Khazragui HF
Drug Discov Today; 2013 Jul; 18(13-14):610-3. PubMed ID: 23402848
[TBL] [Abstract][Full Text] [Related]
16. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery.
Rai AK; Reichman JH; Uhlir PF; Crossman C
Yale J Health Policy Law Ethics; 2008; 8(1):1-36. PubMed ID: 18564492
[No Abstract] [Full Text] [Related]
17. Outcry over plans for 'Japanese NIH'.
Fuyuno I
Nature; 2013 Jul; 499(7457):136-7. PubMed ID: 23846639
[No Abstract] [Full Text] [Related]
18. Academia-pharma partnerships for novel drug discovery: essential or nice to have?
Palmer M; Chaguturu R
Expert Opin Drug Discov; 2017 Jun; 12(6):537-540. PubMed ID: 28394189
[No Abstract] [Full Text] [Related]
19. Newsmaker interview. Francis Collins: on recruiting Varmus, discovering drugs, the funding cliff. Interview by Jocelyn Kaiser.
Collins F
Science; 2010 May; 328(5982):1090-1. PubMed ID: 20508101
[No Abstract] [Full Text] [Related]
20. Partners in discovery.
Fuyuno I
Nature; 2018 Mar; 555(7697):S60. PubMed ID: 29565400
[No Abstract] [Full Text] [Related]
[Next] [New Search]
